Evercore ISI raised the firm’s price target on Editas Medicine (EDIT) to $15 from $8 and keeps an In Line rating on the shares after the company and Vertex Pharmaceuticals (VRTX) entered into a license agreement under which Vertex will obtain a non-exclusive license for Editas’ Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of sickle cell disease and beta thalassemia, including Casgevy. This first Cas9 license deal extends Editas’ cash runway to 2026 from Q3 of 2025 prior to this announcement, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
- Editas Medicine price target raised by $5 at Truist, here’s why
- Editas Medicine to hold a pharmaceutical update conference call
- Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
- Editas presents new EDIT-301 safety and efficacy data in 17 patients
